Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai Yarkoni with a vision of enabling regenerative medicine to become reality. Realizing that stem cells are one of the pillars of the 21st century medicine, first development was around enabling the mass enrichment of stem cells as a raw material for any and all regenerative treatments. Without such technologies, stem cells based treatments will remain within the confines of laboratories and clinical trials. For regenerative medicine to become publicly available for all people, quality stem cells need to become a commodity, easily available in mass for all medicinal purposes. Cellect was driven by its wish to become the main provider of technologies for pharma companies and medical centers that will make the production of stem cells based products a trivial, safe and inexpensive process. Source
No articles found.
Otsuka Holdings Co Ltd is a pharmaceutical company. The Company manufactures, sell...
Otsuka Holdings Co Ltd is a pharmaceutical comp...
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...
Alexion (NASDAQ: ALXN) is a global biopharmaceu...
Halozyme is a clinical-stage biotechnology company focused on developing and comme...
Halozyme is a clinical-stage biotechnology comp...
iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solut...
iCAD, Inc. an industry-leading provider of adva...
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device compan...
Cardiovascular Systems, Inc., based in St. Paul...
Cesca is a leading regenerative medicine company that develops, commercializes and...
Cesca is a leading regenerative medicine compan...
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerati...
BioCardia, Inc., headquartered in San Carlos, C...
Join the National Investor Network and get the latest information with your interests in mind.